See more : Hankyu Hanshin Holdings, Inc. (9042.T) Income Statement Analysis – Financial Results
Complete financial analysis of SITE Centers Corp. (SITC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SITE Centers Corp., a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- Manjeera Constructions Limited (MANJEERA.BO) Income Statement Analysis – Financial Results
- Swiss Life Holding AG (SZLMY) Income Statement Analysis – Financial Results
- FILA Holdings Corporation (081660.KS) Income Statement Analysis – Financial Results
- L&C Bio Co., Ltd (290650.KQ) Income Statement Analysis – Financial Results
- Public Joint-Stock Company Pharmacy Chain 36.6 (APTK.ME) Income Statement Analysis – Financial Results
SITE Centers Corp. (SITC)
About SITE Centers Corp.
SITE Centers is an owner and manager of open-air shopping centers that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 546.28M | 540.81M | 492.34M | 416.76M | 447.75M | 654.86M | 879.45M | 969.51M | 995.10M | 953.77M | 888.79M | 800.38M | 771.02M | 803.07M | 819.31M | 931.47M | 944.85M | 818.10M | 727.18M | 598.93M | 476.10M | 357.24M | 322.24M | 285.79M | 263.93M | 228.17M | 169.04M | 130.91M | 108.60M | 81.80M | 51.70M |
| Cost of Revenue | 165.72M | 169.98M | 152.79M | 138.40M | 139.66M | 207.99M | 250.92M | 277.08M | 293.69M | 281.11M | 255.35M | 233.08M | 235.80M | 246.16M | 254.47M | 257.12M | 133.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 380.55M | 370.82M | 339.56M | 278.36M | 308.09M | 446.87M | 628.53M | 692.42M | 701.41M | 672.66M | 633.44M | 567.30M | 535.22M | 556.91M | 564.84M | 674.35M | 811.52M | 818.10M | 727.18M | 598.93M | 476.10M | 357.24M | 322.24M | 285.79M | 263.93M | 228.17M | 169.04M | 130.91M | 108.60M | 81.80M | 51.70M |
| Gross Profit Ratio | 69.66% | 68.57% | 68.97% | 66.79% | 68.81% | 68.24% | 71.47% | 71.42% | 70.49% | 70.53% | 71.27% | 70.88% | 69.42% | 69.35% | 68.94% | 72.40% | 85.89% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 50.87M | 46.56M | 55.05M | 52.88M | 58.38M | 61.64M | 89.85M | 76.10M | 73.38M | 84.48M | 79.56M | 76.44M | 85.22M | 85.57M | 94.37M | 97.72M | 81.24M | 60.68M | 54.05M | 47.13M | 40.82M | 29.39M | 24.38M | 20.45M | 17.77M | 12.92M | 11.06M | 8.44M | 6.40M | 5.60M | 4.10M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.36M | -15.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.87M | 46.56M | 55.05M | 52.88M | 58.38M | 61.64M | 89.85M | 76.10M | 73.38M | 84.48M | 79.56M | 76.44M | 85.22M | 85.57M | 79.00M | 81.88M | 81.24M | 60.68M | 54.05M | 47.13M | 40.82M | 29.39M | 24.38M | 20.45M | 17.77M | 12.92M | 11.06M | 8.44M | 6.40M | 5.60M | 4.10M |
| Other Expenses | 0.00 | 203.55M | 185.77M | 170.67M | 165.09M | 242.10M | -95.36M | 39.62M | 31.23M | 19.65M | -6.63M | -17.88M | 222.66M | 222.86M | 227.19M | 242.03M | 328.08M | 401.31M | 349.01M | 281.19M | 436.63M | 326.34M | 302.62M | 114.62M | 104.34M | 204.15M | 139.39M | 111.53M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 45.87M | 250.11M | 240.82M | 223.55M | 223.47M | 303.74M | 446.85M | 465.62M | 475.43M | 487.31M | 397.63M | 325.23M | 307.88M | 308.44M | 321.55M | 596.87M | 409.32M | 461.99M | 403.06M | 328.32M | 477.45M | 355.73M | 326.99M | 135.07M | 122.11M | 217.07M | 150.45M | 119.96M | -43.60M | -33.40M | -23.10M |
| Cost & Expenses | 430.47M | 420.09M | 393.61M | 361.95M | 363.13M | 511.73M | 697.77M | 742.70M | 769.12M | 768.42M | 652.99M | 558.30M | 543.67M | 554.60M | 576.02M | 596.87M | 542.66M | 461.99M | 403.06M | 328.32M | 477.45M | 355.73M | 326.99M | 135.07M | 122.11M | 217.07M | 150.45M | 119.96M | -43.60M | -33.40M | -23.10M |
| Interest Income | 0.00 | 0.00 | 0.00 | 11.89M | 18.01M | 20.44M | 28.36M | 37.05M | 29.21M | 15.93M | 23.54M | 15.80M | 9.83M | 7.35M | 12.11M | 5.47M | 8.81M | 0.00 | 0.00 | 0.00 | 5.08M | 5.91M | 6.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 82.00M | 77.69M | 77.03M | 77.60M | 84.72M | 141.31M | 188.65M | 217.59M | 241.73M | 237.12M | 228.87M | 221.42M | 229.72M | 226.46M | 237.94M | 244.21M | 258.15M | 0.00 | 0.00 | 0.00 | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Depreciation & Amortization | 212.46M | 203.55M | 185.77M | 170.67M | 165.09M | 242.10M | 346.20M | 389.52M | 402.05M | 402.83M | 318.08M | 248.78M | 222.66M | 222.86M | 227.19M | 242.03M | 224.38M | 193.53M | 170.70M | 132.65M | 95.22M | 78.37M | 64.49M | 54.20M | 52.44M | 43.18M | 32.31M | 25.06M | 23.60M | 17.40M | 10.90M |
| EBITDA | 339.27M | 361.16M | 372.32M | 263.06M | 323.04M | 338.23M | 577.39M | 667.87M | 656.21M | 634.70M | 514.62M | 456.09M | 230.11M | 252.22M | 244.64M | 337.90M | 629.59M | 549.64M | 494.82M | 403.26M | 417.48M | 222.98M | 64.49M | 196.19M | 415.86M | 359.46M | 285.80M | 218.10M | 175.80M | 132.60M | 85.70M |
| EBITDA Ratio | 62.11% | 66.78% | 75.62% | 63.12% | 72.15% | 51.65% | 53.41% | 73.10% | 68.87% | 66.55% | 64.99% | 65.47% | 61.42% | 60.30% | 60.63% | 52.91% | 66.63% | 67.24% | 68.39% | 67.63% | 19.72% | 22.36% | 18.54% | 71.70% | 73.60% | 23.68% | 28.03% | 27.51% | 161.60% | 162.10% | 165.76% |
| Operating Income | 339.27M | 157.61M | 186.55M | 92.39M | 157.95M | 96.12M | 637.03M | 692.42M | 701.41M | 672.66M | 221.41M | 196.76M | 214.91M | 65.10M | -119.34M | 169.00M | 261.41M | 250.78M | 282.99M | 271.23M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Operating Income Ratio | 62.11% | 29.14% | 37.89% | 22.17% | 35.28% | 14.68% | 72.44% | 71.42% | 70.49% | 70.53% | 24.91% | 24.58% | 27.87% | 8.11% | -14.57% | 18.14% | 27.67% | 30.65% | 38.92% | 45.29% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| Total Other Income/Expenses | -71.50M | -188.46M | -12.29M | -62.36M | -41.49M | -76.27M | -456.83M | -273.51M | -490.55M | -194.30M | -510.01M | -113.39M | -250.28M | -211.28M | -198.46M | -279.60M | -71.96M | -182.52M | -139.86M | -86.31M | 73.04M | -38.81M | -74.95M | -67.88M | 0.00 | -314.76M | -252.10M | 0.00 | -152.20M | 0.00 | 0.00 |
| Income Before Tax | 267.77M | 169.61M | 126.97M | 37.72M | 102.48M | -108.44M | -402.67M | -10.41M | -231.60M | 22.96M | 4.60M | -13.62M | -41.54M | -146.18M | -317.80M | -89.94M | 189.90M | 173.59M | 184.26M | 184.31M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Income Before Tax Ratio | 49.02% | 31.36% | 25.79% | 9.05% | 22.89% | -16.56% | -45.79% | -1.07% | -23.27% | 2.41% | 0.52% | -1.70% | -5.39% | -18.20% | -38.79% | -9.66% | 20.10% | 21.22% | 25.34% | 30.77% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| Income Tax Expense | 2.05M | 816.00K | 1.55M | 1.13M | 659.00K | 862.00K | 1.62M | 1.78M | 6.29M | 1.86M | 2.71M | 1.16M | 1.04M | 47.99M | -691.00K | -17.43M | -14.64M | -2.48M | 342.00K | 1.47M | -240.26M | -101.97M | -92.37M | -100.83M | -87.40M | -77.92M | -67.52M | -49.54M | -25.50M | -21.20M | -8.60M |
| Net Income | 265.70M | 168.72M | 124.94M | 35.72M | 100.70M | -109.30M | -241.69M | 60.01M | -72.17M | 117.28M | -10.18M | -25.82M | -15.85M | -209.36M | -356.59M | -57.78M | 276.05M | 253.26M | 282.64M | 269.76M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Net Income Ratio | 48.64% | 31.20% | 25.38% | 8.57% | 22.49% | -16.69% | -27.48% | 6.19% | -7.25% | 12.30% | -1.14% | -3.23% | -2.06% | -26.07% | -43.52% | -6.20% | 29.22% | 30.96% | 38.87% | 45.04% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| EPS | 4.85 | 2.96 | 2.04 | 0.74 | 2.20 | -2.37 | -5.26 | 1.31 | -1.60 | 2.00 | -0.25 | -0.72 | -0.47 | -6.84 | -17.96 | -3.48 | 13.41 | 13.12 | 15.14 | 16.37 | 16.66 | 11.55 | 12.07 | 12.95 | 10.27 | 9.89 | 7.43 | 6.06 | 4.61 | 4.83 | 2.74 |
| EPS Diluted | 4.85 | 2.92 | 2.04 | 0.74 | 2.20 | -2.37 | -5.26 | 1.31 | -1.60 | 2.00 | -0.25 | -0.72 | -0.47 | -6.84 | -17.96 | -3.47 | 13.34 | 13.05 | 15.00 | 16.15 | 16.37 | 11.34 | 11.97 | 12.95 | 9.96 | 9.50 | 7.43 | 5.99 | 4.61 | 4.76 | 2.74 |
| Weighted Avg Shares Out | 52.36M | 53.25M | 52.00M | 48.33M | 45.76M | 46.13M | 45.92M | 45.66M | 45.11M | 44.76M | 40.80M | 35.88M | 33.78M | 30.59M | 19.85M | 16.62M | 16.76M | 15.09M | 15.02M | 13.38M | 11.35M | 8.83M | 7.65M | 7.79M | 8.51M | 7.88M | 7.18M | 7.66M | 5.53M | 4.39M | 3.14M |
| Weighted Avg Shares Out (Dil) | 52.41M | 53.47M | 52.29M | 48.44M | 45.81M | 46.13M | 45.92M | 45.70M | 45.11M | 44.76M | 40.80M | 35.88M | 33.93M | 30.59M | 19.85M | 16.64M | 16.85M | 15.18M | 15.17M | 13.56M | 11.55M | 8.99M | 7.72M | 7.79M | 8.78M | 8.20M | 7.18M | 7.66M | 5.53M | 4.45M | 3.14M |
SITE CENTERS CORP. (SITC) Q3 FFO and Revenues Miss Estimates
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.81 per share, missing the Zacks Consensus Estimate of $0.87 per share.
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of...
SITE Centers Reports Third Quarter 2024 Results
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers primarily in suburban, high household income communities, announced today operating results for the quarter ended September 30, 2024. "SITE Centers completed the planned spin-off of Curbline Properties...
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company...
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif. , Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1...
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society...
67 October Graham All-Star Value Dogs Show 55 Fit To Buy
The Value Score identifies large-cap stocks offering high-value relative to profits, cash flows, assets and sales, aiding in finding undervalued companies.
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for...
SITE Centers' Third Quarter 2024 Earnings to be Released Wednesday, October 30, 2024
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC) announced today that it intends to release its third quarter earnings prior to the market open on October 30, 2024. About SITE Centers Corp. SITE Centers is an owner and manager of open-air...
Source: https://incomestatements.info
Category: Stock Reports